What's new? Log in Free sign up

Biodexa Pharmaceuticals (BDRX)

Company Profile

Company profile

Ticker

BDRX

Exchange

Website

www.biodexapharma.com

CEO

Mr. Stephen Anthony Stamp

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Midatech Pharma Plc

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

BDRX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Current report (foreign)

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Prospectus supplement

Notice of effectiveness

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Prospectus supplement

Prospectus supplement

Prospectus supplement

Prospectus supplement

Transcripts

Earnings call transcript

Latest ownership filings

View all

C/M CAPITAL PARTNERS, LP

Brio Capital Master Fund Ltd.

Iroquois Capital Management, LLC

Bigger Capital, LLC

Cavalry Fund I LP

Iroquois Capital Management, LLC

Brio Capital Master Fund Ltd.

Ionic Ventures, LLC

ARMISTICE CAPITAL, LLC

CVI Investments, Inc.

Financial summary

Financial statements Chart BDRX financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

BDRX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	9	7	+28.6%
Opened positions	3	2	+50.0%
Closed positions	1	10	-90.0%
Increased positions	0	0
Reduced positions	2	1	+100.0%

13F shares	Current	Prev Q	Change
Total value	328.16 mm	299.96 mm	+9.4%
Total shares	139.93 mm	141.19 mm	-0.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Cavalry Fund I	110.56 mm	$279.71 mm	0.0%
IOI Ionic Ventures	18.04 mm	$11.36 mm	0.0%
CVI Investments	10.83 mm	$6.88 mm	0.0%
Iroquois Capital Management	327.66 k	$262.00 k	0.0%
Brio Capital Master Fund	167.68 k	$612.00 k	-88.3%
UBS UBS	7.05 k	$28.54 mm	NEW
Rhumbline Advisers	154.00	$628.00 k	NEW
Contravisory Investment Management	40.00	$162.00 k	-96.0%
SBI Securities	1.00	$4.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Brio Capital Master Fund	167.68 k	-1.26 mm	-88.3%
UBS UBS	7.05 k	+7.05 k	NEW
Contravisory Investment Management	40.00	-960.00	-96.0%
GAMMA Investing	0.00	-287.00	EXIT
Rhumbline Advisers	154.00	+154.00	NEW
SBI Securities	1.00	+1.00	NEW
Proequities	0.00	0.00
Iroquois Capital Management	327.66 k	0.00	0.0%
CVI Investments	10.83 mm	0.00	0.0%
Cavalry Fund I	110.56 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Biodexa Wins FDA Fast Track for eRapa, Targets Familial Adenomatous Polyposis Treatment

Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Crude Oil Rises Sharply; Manhattan Associates Shares Slide

Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss

Press releases

From Benzinga Pro

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use

February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.